140 related articles for article (PubMed ID: 31307108)
1. Metabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma.
Dwight T; Kim E; Novos T; Clifton-Bligh RJ
Horm Metab Res; 2019 Jul; 51(7):443-450. PubMed ID: 31307108
[TBL] [Abstract][Full Text] [Related]
2. Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Richter S; Gieldon L; Pang Y; Peitzsch M; Huynh T; Leton R; Viana B; Ercolino T; Mangelis A; Rapizzi E; Menschikowski M; Aust D; Kroiss M; Beuschlein F; Gudziol V; Timmers HJ; Lenders J; Mannelli M; Cascon A; Pacak K; Robledo M; Eisenhofer G; Klink B
Genet Med; 2019 Mar; 21(3):705-717. PubMed ID: 30050099
[TBL] [Abstract][Full Text] [Related]
3. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics in paraganglioma: applications and perspectives from genetics to therapy.
Richter S; Garrett TJ; Bechmann N; Clifton-Bligh RJ; Ghayee HK
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36897220
[TBL] [Abstract][Full Text] [Related]
5. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic Urine Profile: Searching for New Biomarkers of SDHx-Associated Pheochromocytomas and Paragangliomas.
Martins RG; Gonçalves LG; Cunha N; Bugalho MJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5467-5477. PubMed ID: 31504671
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes.
Toledo RA; Dahia PL
Curr Opin Endocrinol Diabetes Obes; 2015 Jun; 22(3):169-79. PubMed ID: 25871962
[TBL] [Abstract][Full Text] [Related]
8. Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas.
Remacha L; Comino-Méndez I; Richter S; Contreras L; Currás-Freixes M; Pita G; Letón R; Galarreta A; Torres-Pérez R; Honrado E; Jiménez S; Maestre L; Moran S; Esteller M; Satrústegui J; Eisenhofer G; Robledo M; Cascón A
Clin Cancer Res; 2017 Oct; 23(20):6315-6324. PubMed ID: 28720665
[No Abstract] [Full Text] [Related]
9. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
[TBL] [Abstract][Full Text] [Related]
10. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma.
Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F
Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135
[TBL] [Abstract][Full Text] [Related]
12. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
13. Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors.
März J; Kurlbaum M; Roche-Lancaster O; Deutschbein T; Peitzsch M; Prehn C; Weismann D; Robledo M; Adamski J; Fassnacht M; Kunz M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():722656. PubMed ID: 34557163
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
[TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
Khatami F; Mohammadamoli M; Tavangar SM
Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
[TBL] [Abstract][Full Text] [Related]
16. Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics.
Rao JU; Engelke UF; Sweep FC; Pacak K; Kusters B; Goudswaard AG; Hermus AR; Mensenkamp AR; Eisenhofer G; Qin N; Richter S; Kunst HP; Timmers HJ; Wevers RA
J Clin Endocrinol Metab; 2015 Feb; 100(2):E214-22. PubMed ID: 25459911
[TBL] [Abstract][Full Text] [Related]
17. [Pheochromocytomas and paragangliomas: implications of new insights for diagnosis and treatment].
van der Kleij-Corssmit EP; Havekes B; Vriends AH; Jansen JC; Romijn JA
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):489-93. PubMed ID: 18389879
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
19. The Role of Immunohistochemistry and Molecular Analysis of Succinate Dehydrogenase in the Diagnosis of Endocrine and Non-Endocrine Tumors and Related Syndromes.
Oudijk L; Gaal J; de Krijger RR
Endocr Pathol; 2019 Mar; 30(1):64-73. PubMed ID: 30421319
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]